Efficacy of tumour necrosis factor-α antagonists in aphthous ulceration: Review of published individual patient data

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 2, 2012, Pages 231-235

  O'Neill, I D ^a  

^a Centre d'Affaires Poincare   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PENTOXIFYLLINE; PREDNISONE; RETINOID; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

APHTHOUS ULCER; ARTICLE; BEHCET DISEASE; CROHN DISEASE; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT DISEASE; SYSTEMATIC REVIEW; TREATMENT DURATION;

HUMANS; STOMATITIS, APHTHOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856331241     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04041.x     Document Type: Article

References (48)

1. Scully C,. Clinical practice. Aphthous ulceration. N Engl J Med 2006; 355: 165-172.
2. Keogan MT,. Clinical Immunology Review Series: an approach to the patient with recurrent orogenital ulceration, including Behçet's syndrome. Clin Exp Immunol 2009; 156: 1-11.
3. Letsinger JA, McCarthy MA, Jorizzo JL,. Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J Am Acad Dermatol 2005; 52: 500-508.
4. Ruocco E, Cuomo A, Salerno R, et al. Crohn's disease and its mucocutaneous involvement. Skinmed 2007; 6: 179-185.
5. Kerr AR, Ship JA,. Management strategies for HIV-associated aphthous stomatitis. Am J Clin Dermatol 2003; 4: 669-680. (Pubitemid 37411983)
6. Dale DC, Welte K,. Cyclic and chronic neutropenia. Cancer Treat Res 2011; 157: 97-108.
7. Bruce A, Rogers RS III,. New and old therapeutics for oral ulcerations. Arch Dermatol 2007; 143: 519-523. (Pubitemid 46631652)
8. Lynde CB, Bruce AJ, Rogers RS, III,. Successful treatment of complex aphthosis with colchicine and dapsone. Arch Dermatol 2009; 145: 273-276.
9. Hello M, Barbarot S, Bastuji-Garin S, et al. Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis. Medicine (Baltimore) 2010; 89: 176-182.
10. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443-450.
11. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990; 126: 923-927. (Pubitemid 20224550)
12. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997; 33: 1487-1493. (Pubitemid 27215163)
13. Scully C, Porter S,. Oral mucosal disease: recurrent aphthous stomatitis. Br J Oral Maxillofac Surg 2008; 46: 198-206. (Pubitemid 351329434)
14. Rogers RS 3rd,. Recurrent aphthous stomatitis: clinical characteristics and associated systemic disorders. Semin Cutan Med Surg 1997; 16: 278-283.
15. O'Neill ID,. Off-label use of biologicals in the management of inflammatory oral mucosal disease. J Oral Pathol Med 2008; 37: 575-581.
16. O'Neill I,. Guidance on the use of biological agents in the treatment of oral mucosal disease. Br J Dermatol 2010; 162: 1410-1411.
17. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005; 32: 98-105. (Pubitemid 40092599)
18. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sightthreatening ocular inflammation in Adamantiades-Behcet's disease. Ann Intern Med 2004; 140: 404-406. (Pubitemid 38268925)
19. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004; 31: 1362-1368. (Pubitemid 38879203)
20. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of Infliximab in the treatment of uveitis that is refractory to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in behcet's disease. An open-label trial. Arthritis Rheum 2005; 52: 2478-2484. (Pubitemid 41117435)
21. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease - review and basis for recommendations. Rheumatology (Oxford) 2007; 46: 736-741. (Pubitemid 47061701)
22. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-1662.
23. Robertson LP, Hickling P,. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology (Oxford) 2001; 40: 473-474. (Pubitemid 32409564)
24. Connolly M, Armstrong JS, Buckley DA,. Infliximab treatment for severe orogenital ulceration in Behçet's disease. Br J Dermatol 2005; 153: 1073-1075. (Pubitemid 41540787)
25. Almoznino G, Ben-Chetrit E,. Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature. Clin Exp Rheumatol 2007; 25: S99-S102.
26. Estrach C, Mpofu S, Moots RJ,. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 2002; 41: 1213-1214. (Pubitemid 35203564)
27. Aikawa NE, Gonçalves C, Silva CA, et al. Late response to anti-TNF-alpha therapy in refractory mucocutaneous lesions of Behçet's disease. Rheumatol Int 2009; doi: 10.1007/s00296-009-1276-x. PMID 20012049. Dec 11 [Epub ahead of print].
28. Goossens PH, Verburg RJ, Breedveld FC,. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis 2001; 60: 637. (Pubitemid 32493994)
29. Jacobi A, Debus D, Schuler G, Hertl M,. Infliximab in a patient with refractory mucosal aphthosis. J Eur Acad Dermatol Venereol 2008; 22: 109-110.
30. Scheinberg MA,. Treatment of recurrent oral aphthous ulcers with etanercept. Clin Exp Rheumatol 2002; 20: 733-734. (Pubitemid 35243794)
31. Atzeni F, Sarzi-Puttini P, Capsoni F, et al. Successful treatment of resistant Behçet's disease with etanercept. Clin Exp Rheumatol 2005; 23: 729. (Pubitemid 41300729)
32. Curigliano V, Giovinale M, Fonnesu C, et al. Efficacy of etanercept in the treatment of a patient with Behçet's disease. Clin Rheumatol 2008; 27: 933-936.
33. Robinson ND, Guitart J,. Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol 2003; 139: 1259-1262. (Pubitemid 37248276)
34. Sanchez AR, Rogers RS III, Sheridan PJ,. Oral ulcerations are associated with the loss of response to infliximab in Crohn's disease. J Oral Pathol Med 2005; 34: 53-55. (Pubitemid 40142930)
35. Vujevich J, Zirwas M,. Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab. Cutis 2005; 76: 29-32.
36. Sánchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, Ortego-Centeno N,. Recalcitrant, recurrent aphthous stomatitis successfully treated with adalimumab. J Eur Acad Dermatol Venereol 2009; 23: 206.
37. Kaufman I, Caspi D, Yeshurun D, et al. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int 2005; 25: 406-410. (Pubitemid 41186906)
38. van Laar J, Missotten T, van Daele PL, et al. Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis 2007; 66: 565-566. (Pubitemid 46580490)
39. Haugeberg G, Velken M, Johnsen V,. Successful treatment of genital ulcers with infliximab in Behcet's disease. Ann Rheum Dis 2004; 63: 744-745. (Pubitemid 38658408)
40. Olivieri I, Latanza L, Siringo S, et al. Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete. J Rheumatol 2008; 35: 930-932. (Pubitemid 351747140)
41. Olivieri I, Padula A, Leccese P, et al. Long-lasting remission of severe Behçet's disease after the end of infliximab therapy. J Rheumatol 2009; 36: 855.
42. Calabrese LH, Zein N, Vassilopoulos D,. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63: ii18-ii24. (Pubitemid 39424653)
43. Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 20-34.
44. Domm S, Cinatl J, Mrowietz U,. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217-1228.
45. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
46. Menon K, Van Voorhees AS, Bebo BF, Jr, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62: 291-299.
47. Streit M, Beleznay Z, Braathen LR,. Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J 2006; 3: 171-179.
48. Tam A, Anderson DA,. The treatment of lower leg ulcers with topical etanercept. J Am Osteopath Coll Dermatol 2007; 8: 68-71.